SPY441.40-4.34 -0.97%
DIA345.64-1.80 -0.52%
IXIC15,043.97-137.96 -0.91%

Pfizer Begins Phase 3 Trial of Vaccine Candidate Against Respiratory Syncytial Virus Disease

MT Newswires · 09/02/2021 03:52

Please log in to view news